Name	Melanoma
ICD	ICD-11: 2C30

In total 1 item(s) under this target gene
Experiment 1 Reporting the m6A-centered Disease Response by This Target Gene				[1]
Response Summary	METTL3 is upregulated in human melanoma and plays a role in invasion/migration through MMP2. METTL3 overexpression promotes accumulation of 72 kDa type IV collagenase (MMP2) and N-cadherin in melanoma cells.
Responsed Disease	Melanoma [ICD-11: 2C30]
Target Regulator	Methyltransferase-like 3 (METTL3)		WRITER	Regulator Info
Target Regulation	Up regulation
Cell Process	Cell invasion/migration
In-vitro Model	451Lu	Cutaneous melanoma	Homo sapiens	CVCL_6357
	A-375	Amelanotic melanoma	Homo sapiens	CVCL_0132
	A375-MA2	Amelanotic melanoma	Homo sapiens	CVCL_X495
	MeWo	Cutaneous melanoma	Homo sapiens	CVCL_0445
	SK-MEL-2	Melanoma	Homo sapiens	CVCL_0069
	WM164	Cutaneous melanoma	Homo sapiens	CVCL_7928
	WM3211	Acral lentiginous melanoma	Homo sapiens	CVCL_6797
	WM3918	Melanoma	Homo sapiens	CVCL_C279
	WM793	Melanoma	Homo sapiens	CVCL_8787

In total 1 item(s) under this target gene
Experiment 1 Reporting the m6A-centered Disease Response by This Target Gene				[2]
Response Summary	YTHDF1 promoted the translation of methylated Adenosine 5'-monophosphoramidase HINT2 (HINT2) mRNA, a tumor suppressor in ocular melanoma.
Responsed Disease	Melanoma [ICD-11: 2C30]
Target Regulator	YTH domain-containing family protein 1 (YTHDF1)		READER	Regulator Info
Target Regulation	Up regulation
In-vitro Model	CM2005.1	Conjunctival melanoma	Homo sapiens	CVCL_M592
	CRMM-1	Conjunctival melanoma	Homo sapiens	CVCL_M593
	HEK293T	Normal	Homo sapiens	CVCL_0063
	OCM-1	Amelanotic melanoma	Homo sapiens	CVCL_6934
	OCM-1A	Amelanotic melanoma	Homo sapiens	CVCL_6935
	OM431	Uveal melanoma	Homo sapiens	CVCL_J308
	PIG1	Normal	Homo sapiens	CVCL_S410
In-vivo Model	Approximately 1 × 106 melanoma cells from each group were injected subcutaneously into the right side of the abdomen of BALB/c nude mice (male, 6 weeks old).

In total 1 item(s) under this target gene
Experiment 1 Reporting the m6A-centered Disease Response by This Target Gene				[3]
Response Summary	Beta-site APP-cleaving enzyme 2 (BACE2) presented an increased level of N6-methyladenosine (m6A) RNA methylation, which led to the upregulation of BACE2 mRNA. This study provides a novel pattern of BACE2-mediated intracellular calcium release in ocular melanoma progression.
Responsed Disease	Melanoma of uvea [ICD-11: 2D0Y]
Cell Process	Intracellular calcium release
In-vitro Model	MuM-2B	Uveal melanoma	Homo sapiens	CVCL_3447
	OM431	Uveal melanoma	Homo sapiens	CVCL_J308
	Mel290	Uveal melanoma	Homo sapiens	CVCL_C304
	OMM-1	Uveal melanoma	Homo sapiens	CVCL_6939
	()
	CRMM-1	Conjunctival melanoma	Homo sapiens	CVCL_M593
	CRMM-2	Conjunctival melanoma	Homo sapiens	CVCL_M594
	CM2005.1	Conjunctival melanoma	Homo sapiens	CVCL_M592
	HEK293T	Normal	Homo sapiens	CVCL_0063

In total 2 item(s) under this target gene
Experiment 1 Reporting the m6A-centered Disease Response by This Target Gene				[4]
Response Summary	These findings demonstrate a crucial role of FTO as an m6A demethylase in promoting melanoma tumorigenesis and anti-PD-1 resistance, and suggest that the combination of FTO inhibition with anti-PD-1 blockade reduces the resistance to immunotherapy in melanoma. Knockdown of FTO increases m6A methylation in the critical protumorigenic melanoma cell-intrinsic genes including PD-1 (PDCD1), C-X-C chemokine receptor type 4 (CXCR4), and SOX10, leading to increased RNA decay through the m6A reader YTHDF2.
Responsed Disease	Melanoma [ICD-11: 2C30]
Responsed Drug	PMID31239444-anti-PD1 antibody		Investigative	Drug Info
Target Regulator	Fat mass and obesity-associated protein (FTO)		ERASER	Regulator Info
Target Regulation	Up regulation
Pathway Response	PD-L1 expression and PD-1 checkpoint pathway in cancer			hsa05235
Cell Process	mRNA decay
In-vitro Model	B16-F10	Mouse melanoma	Mus musculus	CVCL_0159
	CHL-1	Melanoma	Homo sapiens	CVCL_1122
	624-mel	Melanoma	Homo sapiens	CVCL_8054
	NHEM (Normal Human Epidermal Melanocytes)
	SK-MEL-30	Cutaneous melanoma	Homo sapiens	CVCL_0039
	WM115	Melanoma	Homo sapiens	CVCL_0040
	WM35	Melanoma	Homo sapiens	CVCL_0580
	WM3670	Melanoma	Homo sapiens	CVCL_6799
	WM793	Melanoma	Homo sapiens	CVCL_8787
In-vivo Model	When the tumors reached a volume of 80-100 mm3, mice were treated with anti-PD-1 or isotype control antibody (200 ug/mouse) by i.p. injection, every other day for three times. For IFNγ blockade treatment, C57BL/6 mice were treated with anti-IFNγ antibody or isotype control IgG (250 ug/mouse) every other day after tumor cell inoculation.
Experiment 2 Reporting the m6A-centered Disease Response by This Target Gene				[4]
Response Summary	These findings demonstrate a crucial role of FTO as an m6A demethylase in promoting melanoma tumorigenesis and anti-PD-1 resistance, and suggest that the combination of FTO inhibition with anti-PD-1 blockade reduces the resistance to immunotherapy in melanoma. Knockdown of FTO increases m6A methylation in the critical protumorigenic melanoma cell-intrinsic genes including PD-1 (PDCD1), C-X-C chemokine receptor type 4 (CXCR4), and SOX10, leading to increased RNA decay through the m6A reader YTHDF2.
Responsed Disease	Melanoma [ICD-11: 2C30]
Responsed Drug	PMID31239444-anti-PD1 antibody		Investigative	Drug Info
Target Regulator	YTH domain-containing family protein 2 (YTHDF2)		READER	Regulator Info
Target Regulation	Down regulation
Pathway Response	PD-L1 expression and PD-1 checkpoint pathway in cancer			hsa05235
Cell Process	mRNA decay
In-vitro Model	B16-F10	Mouse melanoma	Mus musculus	CVCL_0159
	CHL-1	Melanoma	Homo sapiens	CVCL_1122
	624-mel	Melanoma	Homo sapiens	CVCL_8054
	NHEM (Normal Human Epidermal Melanocytes)
	SK-MEL-30	Cutaneous melanoma	Homo sapiens	CVCL_0039
	WM115	Melanoma	Homo sapiens	CVCL_0040
	WM35	Melanoma	Homo sapiens	CVCL_0580
	WM3670	Melanoma	Homo sapiens	CVCL_6799
	WM793	Melanoma	Homo sapiens	CVCL_8787
In-vivo Model	When the tumors reached a volume of 80-100 mm3, mice were treated with anti-PD-1 or isotype control antibody (200 ug/mouse) by i.p. injection, every other day for three times. For IFNγ blockade treatment, C57BL/6 mice were treated with anti-IFNγ antibody or isotype control IgG (250 ug/mouse) every other day after tumor cell inoculation.

In total 1 item(s) under this target gene
Experiment 1 Reporting the m6A-centered Disease Response by This Target Gene				[1]
Response Summary	METTL3 is upregulated in human melanoma and plays a role in invasion/migration through MMP2. METTL3 overexpression promotes accumulation of MMP2 and Cadherin-2 (CDH2/N-cadherin) in melanoma cells.
Responsed Disease	Melanoma [ICD-11: 2C30]
Target Regulator	Methyltransferase-like 3 (METTL3)		WRITER	Regulator Info
Target Regulation	Up regulation
Cell Process	Cell invasion/migration
In-vitro Model	451Lu	Cutaneous melanoma	Homo sapiens	CVCL_6357
	A-375	Amelanotic melanoma	Homo sapiens	CVCL_0132
	A375-MA2	Amelanotic melanoma	Homo sapiens	CVCL_X495
	MeWo	Cutaneous melanoma	Homo sapiens	CVCL_0445
	SK-MEL-2	Melanoma	Homo sapiens	CVCL_0069
	WM164	Cutaneous melanoma	Homo sapiens	CVCL_7928
	WM3211	Acral lentiginous melanoma	Homo sapiens	CVCL_6797
	WM3918	Melanoma	Homo sapiens	CVCL_C279
	WM793	Melanoma	Homo sapiens	CVCL_8787

In total 1 item(s) under this target gene
Experiment 1 Reporting the m6A-centered Disease Response by This Target Gene				[5]
Response Summary	YTHDF3 enhances Catenin beta-1 (CTNNB1/Beta-catenin) translation through recognizing and binding the m6A peaks on CTNNB1 mRNA.m6A reading protein YTHDF3 promotes the translation of the target transcript CTNNB1, contributing to ocular melanoma propagation and migration through m6A methylation.
Responsed Disease	Melanoma of uvea [ICD-11: 2D0Y]
Target Regulator	YTH domain-containing family protein 3 (YTHDF3)		READER	Regulator Info
Target Regulation	Up regulation

In total 1 item(s) under this target gene
Experiment 1 Reporting the m6A-centered Disease Response by This Target Gene				[6]
Response Summary	METTL3 increased the m6A modification of Epidermal growth factor receptor (EGFR) mRNA in A375R cells, which promoted its translation efficiency. Inhibiting METTL3 function to restore PLX4032 sensitivity in patients with melanoma.
Responsed Disease	Melanoma [ICD-11: 2C30]
Responsed Drug	PLX4032		Approved	Drug Info
Target Regulator	Methyltransferase-like 3 (METTL3)		WRITER	Regulator Info
Target Regulation	Up regulation
Pathway Response	EGFR tyrosine kinase inhibitor resistance			hsa01521
Cell Process	Cell apoptosis
In-vitro Model	A375-R	Amelanotic melanoma	Homo sapiens	CVCL_6234

In total 1 item(s) under this target gene
Experiment 1 Reporting the m6A-centered Disease Response by This Target Gene				[7]
Response Summary	In skin cutaneous melanoma, drug sensitivity analysis indicated that the high expression of Interferon-induced 54 kDa protein (IFIT2) was sensitive to dasatinib drug. The expressing levels of IFITs were found to be positively correlated with the level of immune cell infiltrates, immune biomarkers and m6A regulators.
Responsed Disease	Melanoma of skin [ICD-11: 2C30.Z]
Responsed Drug	Dasatinib		Approved	Drug Info
Cell Process	Cell apoptosis
	Epithelial-mesenchymal transition
	Cell cycle

In total 2 item(s) under this target gene
Experiment 1 Reporting the m6A-centered Disease Response by This Target Gene				[4]
Response Summary	These findings demonstrate a crucial role of FTO as an m6A demethylase in promoting melanoma tumorigenesis and anti-PD-1 resistance, and suggest that the combination of FTO inhibition with anti-PD-1 blockade reduces the resistance to immunotherapy in melanoma. Knockdown of FTO increases m6A methylation in the critical protumorigenic melanoma cell-intrinsic genes including Programmed cell death 1 (PD-1) (PDCD1), CXCR4, and SOX10, leading to increased RNA decay through the m6A reader YTHDF2.
Responsed Disease	Melanoma [ICD-11: 2C30]
Responsed Drug	PMID31239444-anti-PD1 antibody		Investigative	Drug Info
Target Regulator	Fat mass and obesity-associated protein (FTO)		ERASER	Regulator Info
Target Regulation	Up regulation
Pathway Response	PD-L1 expression and PD-1 checkpoint pathway in cancer			hsa05235
Cell Process	mRNA decay
In-vitro Model	B16-F10	Mouse melanoma	Mus musculus	CVCL_0159
	CHL-1	Melanoma	Homo sapiens	CVCL_1122
	624-mel	Melanoma	Homo sapiens	CVCL_8054
	NHEM (Normal Human Epidermal Melanocytes)
	SK-MEL-30	Cutaneous melanoma	Homo sapiens	CVCL_0039
	WM115	Melanoma	Homo sapiens	CVCL_0040
	WM35	Melanoma	Homo sapiens	CVCL_0580
	WM3670	Melanoma	Homo sapiens	CVCL_6799
	WM793	Melanoma	Homo sapiens	CVCL_8787
In-vivo Model	When the tumors reached a volume of 80-100 mm3, mice were treated with anti-PD-1 or isotype control antibody (200 ug/mouse) by i.p. injection, every other day for three times. For IFNγ blockade treatment, C57BL/6 mice were treated with anti-IFNγ antibody or isotype control IgG (250 ug/mouse) every other day after tumor cell inoculation.
Experiment 2 Reporting the m6A-centered Disease Response by This Target Gene				[4]
Response Summary	These findings demonstrate a crucial role of FTO as an m6A demethylase in promoting melanoma tumorigenesis and anti-PD-1 resistance, and suggest that the combination of FTO inhibition with anti-PD-1 blockade reduces the resistance to immunotherapy in melanoma. Knockdown of FTO increases m6A methylation in the critical protumorigenic melanoma cell-intrinsic genes including Programmed cell death 1 (PD-1) (PDCD1), CXCR4, and SOX10, leading to increased RNA decay through the m6A reader YTHDF2.
Responsed Disease	Melanoma [ICD-11: 2C30]
Responsed Drug	PMID31239444-anti-PD1 antibody		Investigative	Drug Info
Target Regulator	YTH domain-containing family protein 2 (YTHDF2)		READER	Regulator Info
Target Regulation	Down regulation
Pathway Response	PD-L1 expression and PD-1 checkpoint pathway in cancer			hsa05235
Cell Process	mRNA decay
In-vitro Model	B16-F10	Mouse melanoma	Mus musculus	CVCL_0159
	CHL-1	Melanoma	Homo sapiens	CVCL_1122
	624-mel	Melanoma	Homo sapiens	CVCL_8054
	NHEM (Normal Human Epidermal Melanocytes)
	SK-MEL-30	Cutaneous melanoma	Homo sapiens	CVCL_0039
	WM115	Melanoma	Homo sapiens	CVCL_0040
	WM35	Melanoma	Homo sapiens	CVCL_0580
	WM3670	Melanoma	Homo sapiens	CVCL_6799
	WM793	Melanoma	Homo sapiens	CVCL_8787
In-vivo Model	When the tumors reached a volume of 80-100 mm3, mice were treated with anti-PD-1 or isotype control antibody (200 ug/mouse) by i.p. injection, every other day for three times. For IFNγ blockade treatment, C57BL/6 mice were treated with anti-IFNγ antibody or isotype control IgG (250 ug/mouse) every other day after tumor cell inoculation.

In total 1 item(s) under this target gene
Experiment 1 Reporting the m6A-centered Disease Response by This Target Gene				[8]
Response Summary	METTL3 regulates certain m6A-methylated transcripts, Thioredoxin domain-containing protein 5 (TXNDC5), targeting the m6A dependent-METTL3 signaling pathway serves as a promising therapeutic strategy for management of patients of acral melanomas.
Responsed Disease	Melanoma [ICD-11: 2C30]
Target Regulator	Methyltransferase-like 3 (METTL3)		WRITER	Regulator Info
Target Regulation	Up regulation
Cell Process	Cell proliferation, cell migration,cell invasion
In-vitro Model	SK-MEL-28	Cutaneous melanoma	Homo sapiens	CVCL_0526
	MV3	Amelanotic melanoma	Homo sapiens	CVCL_W280
	HMY-1	Melanoma	Homo sapiens	CVCL_2950
	HEMa (The normal human epidermal melanocyte (HEMa) was extracted from fresh foreskin tissue donated after circumcision in adults and cultured in melanocyte medium with 5% fetal bovine serum (Sciencell, USA))
	A-875	Melanoma	Homo sapiens	CVCL_4733
	A375-MA2	Amelanotic melanoma	Homo sapiens	CVCL_X495
	A2058	Amelanotic melanoma	Homo sapiens	CVCL_1059
In-vivo Model	Sixteen BALB/c nude mice (male, 6-week-old) were raised under pathogen-free conditions and randomly divided into two groups. A total of 2 × 106 A375 NTC or sh-METTL3#2 cells were subcutaneously inoculated into the right hind flank. Body weight and tumor size were measured every other day. The tumors were harvested at the end of the observation period, and tumor weight and gross images were recorded (11 days after inoculation). The tumors were embedded in RNA later and 10% formalin for further detection.

In total 2 item(s) under this target gene
Experiment 1 Reporting the m6A-centered Disease Response by This Target Gene				[4]
Response Summary	These findings demonstrate a crucial role of FTO as an m6A demethylase in promoting melanoma tumorigenesis and anti-PD-1 resistance, and suggest that the combination of FTO inhibition with anti-PD-1 blockade reduces the resistance to immunotherapy in melanoma. Knockdown of FTO increases m6A methylation in the critical protumorigenic melanoma cell-intrinsic genes including PD-1 (PDCD1), CXCR4, and Transcription factor SOX-10 (SOX10), leading to increased RNA decay through the m6A reader YTHDF2.
Responsed Disease	Melanoma [ICD-11: 2C30]
Responsed Drug	PMID31239444-anti-PD1 antibody		Investigative	Drug Info
Target Regulator	YTH domain-containing family protein 2 (YTHDF2)		READER	Regulator Info
Target Regulation	Down regulation
Pathway Response	PD-L1 expression and PD-1 checkpoint pathway in cancer			hsa05235
Cell Process	mRNA decay
In-vitro Model	B16-F10	Mouse melanoma	Mus musculus	CVCL_0159
	CHL-1	Melanoma	Homo sapiens	CVCL_1122
	624-mel	Melanoma	Homo sapiens	CVCL_8054
	NHEM (Normal Human Epidermal Melanocytes)
	SK-MEL-30	Cutaneous melanoma	Homo sapiens	CVCL_0039
	WM115	Melanoma	Homo sapiens	CVCL_0040
	WM35	Melanoma	Homo sapiens	CVCL_0580
	WM3670	Melanoma	Homo sapiens	CVCL_6799
	WM793	Melanoma	Homo sapiens	CVCL_8787
In-vivo Model	When the tumors reached a volume of 80-100 mm3, mice were treated with anti-PD-1 or isotype control antibody (200 ug/mouse) by i.p. injection, every other day for three times. For IFNγ blockade treatment, C57BL/6 mice were treated with anti-IFNγ antibody or isotype control IgG (250 ug/mouse) every other day after tumor cell inoculation.
Experiment 2 Reporting the m6A-centered Disease Response by This Target Gene				[4]
Response Summary	These findings demonstrate a crucial role of FTO as an m6A demethylase in promoting melanoma tumorigenesis and anti-PD-1 resistance, and suggest that the combination of FTO inhibition with anti-PD-1 blockade reduces the resistance to immunotherapy in melanoma. Knockdown of FTO increases m6A methylation in the critical protumorigenic melanoma cell-intrinsic genes including PD-1 (PDCD1), CXCR4, and Transcription factor SOX-10 (SOX10), leading to increased RNA decay through the m6A reader YTHDF2.
Responsed Disease	Melanoma [ICD-11: 2C30]
Responsed Drug	PMID31239444-anti-PD1 antibody		Investigative	Drug Info
Target Regulator	Fat mass and obesity-associated protein (FTO)		ERASER	Regulator Info
Target Regulation	Up regulation
Pathway Response	PD-L1 expression and PD-1 checkpoint pathway in cancer			hsa05235
Cell Process	mRNA decay
In-vitro Model	B16-F10	Mouse melanoma	Mus musculus	CVCL_0159
	CHL-1	Melanoma	Homo sapiens	CVCL_1122
	624-mel	Melanoma	Homo sapiens	CVCL_8054
	NHEM (Normal Human Epidermal Melanocytes)
	SK-MEL-30	Cutaneous melanoma	Homo sapiens	CVCL_0039
	WM115	Melanoma	Homo sapiens	CVCL_0040
	WM35	Melanoma	Homo sapiens	CVCL_0580
	WM3670	Melanoma	Homo sapiens	CVCL_6799
	WM793	Melanoma	Homo sapiens	CVCL_8787
In-vivo Model	When the tumors reached a volume of 80-100 mm3, mice were treated with anti-PD-1 or isotype control antibody (200 ug/mouse) by i.p. injection, every other day for three times. For IFNγ blockade treatment, C57BL/6 mice were treated with anti-IFNγ antibody or isotype control IgG (250 ug/mouse) every other day after tumor cell inoculation.

In total 1 item(s) under this target gene
Experiment 1 Reporting the m6A-centered Disease Response by This Target Gene				[9]
Response Summary	m6A-METTL3 axis induced abnormal Uridine-cytidine kinase 2 (UCK2) expression plays a role in melanoma metastasis by enhancing the Wnt/Bete-catenin pathway, which provided new clues for melanoma metastasis. It also provides a potential target for the prevention and treatment of melanoma.
Responsed Disease	Melanoma [ICD-11: 2C30]
Target Regulator	Methyltransferase-like 3 (METTL3)		WRITER	Regulator Info
Target Regulation	Up regulation
Pathway Response	Wnt signaling pathway			hsa04310
In-vitro Model	Hs 294T	Melanoma	Homo sapiens	CVCL_0331

In total 1 item(s) under this target gene
Experiment 1 Reporting the m6A-centered Disease Response by This Target Gene				[10]
Response Summary	CDR1 antisense RNA (CDR1-AS) a regulator of miR-7, as a hallmark of melanoma progression. CDR1as depletion results from epigenetic silencing of LINC00632, its originating long non-coding RNA (lncRNA) and promotes invasion in vitro and metastasis in vivo through a miR-7-independent, IGF2BP3-mediated mechanism. IGF2BP3 interacts with CDR1as and mediates invasion induced by CDR1as depletion. CDR1asHigh melanoma cell lines were strikingly more sensitive to three different GPX4 inhibitors, which are known to elicit ferroptotic cell death.
Responsed Disease	Melanoma [ICD-11: 2C30]
Responsed Drug	ML-210		Investigative	Drug Info
Target Regulator	Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3)		READER	Regulator Info
Target Regulation	Up regulation
In-vitro Model	451Lu	Cutaneous melanoma	Homo sapiens	CVCL_6357
	501-mel	Melanoma	Homo sapiens	CVCL_4633
	A-375	Amelanotic melanoma	Homo sapiens	CVCL_0132
	SK-MEL-147	Melanoma	Homo sapiens	CVCL_3876
	SK-MEL-173	Melanoma	Homo sapiens	CVCL_6090
	SK-MEL-2	Melanoma	Homo sapiens	CVCL_0069
	SK-MEL-239	Melanoma	Homo sapiens	CVCL_6122
	SK-MEL-28	Cutaneous melanoma	Homo sapiens	CVCL_0526
	WM115	Melanoma	Homo sapiens	CVCL_0040
	WM1361A	Cutaneous melanoma	Homo sapiens	CVCL_6788
	WM1552C	Cutaneous melanoma	Homo sapiens	CVCL_6472
	WM266-4	Melanoma	Homo sapiens	CVCL_2765
	WM278	Cutaneous melanoma	Homo sapiens	CVCL_6473
	WM35	Melanoma	Homo sapiens	CVCL_0580
	WM793b (Immunodeficient mice Cell Type melanocyte)
	WM902B	Melanoma	Homo sapiens	CVCL_6807
In-vivo Model	4-6 weeks old NOD/Shi-scid/IL-2Rgamma null (NOD.Cg-PrkdcscidIl2rgtm1Wjl/SzJ (NSG)) mice (female).

Ref 1	RNA m6A methyltransferase METTL3 regulates invasiveness of melanoma cells by matrix metallopeptidase 2. Melanoma Res. 2019 Aug;29(4):382-389. doi: 10.1097/CMR.0000000000000580.
Ref 2	m(6)A modification suppresses ocular melanoma through modulating HINT2 mRNA translation. Mol Cancer. 2019 Nov 14;18(1):161. doi: 10.1186/s12943-019-1088-x.
Ref 3	m(6)A RNA hypermethylation-induced BACE2 boosts intracellular calcium release and accelerates tumorigenesis of ocular melanoma. Mol Ther. 2021 Jun 2;29(6):2121-2133. doi: 10.1016/j.ymthe.2021.02.014. Epub 2021 Feb 15.
Ref 4	m(6)A mRNA demethylase FTO regulates melanoma tumorigenicity and response to anti-PD-1 blockade. Nat Commun. 2019 Jun 25;10(1):2782. doi: 10.1038/s41467-019-10669-0.
Ref 5	The m(6)A reading protein YTHDF3 potentiates tumorigenicity of cancer stem-like cells in ocular melanoma through facilitating CTNNB1 translation. Oncogene. 2022 Feb;41(9):1281-1297. doi: 10.1038/s41388-021-02146-0. Epub 2022 Feb 3.
Ref 6	METTL3 induces PLX4032 resistance in melanoma by promoting m(6)A-dependent EGFR translation. Cancer Lett. 2021 Dec 1;522:44-56. doi: 10.1016/j.canlet.2021.09.015. Epub 2021 Sep 13.
Ref 7	Comprehensive analysis of the prognosis and biological significance for IFIT family in skin cutaneous melanoma. Int Immunopharmacol. 2021 Dec;101(Pt A):108344. doi: 10.1016/j.intimp.2021.108344. Epub 2021 Nov 8.
Ref 8	m(6)A Methyltransferase METTL3 Promotes the Progression of Primary Acral Melanoma via Mediating TXNDC5 Methylation. Front Oncol. 2022 Jan 18;11:770325. doi: 10.3389/fonc.2021.770325. eCollection 2021.
Ref 9	METTL3-induced UCK2 m(6)A hypermethylation promotes melanoma cancer cell metastasis via the WNT/Beta-catenin pathway. Ann Transl Med. 2021 Jul;9(14):1155. doi: 10.21037/atm-21-2906.
Ref 10	Epigenetic Silencing of CDR1as Drives IGF2BP3-Mediated Melanoma Invasion and Metastasis. Cancer Cell. 2020 Jan 13;37(1):55-70.e15. doi: 10.1016/j.ccell.2019.12.007.